INTRODUCTION AND OBJECTIVES: Both weight loss and low carbohydrate (carb) diets (LCD) without weight loss (0-20% carb kcals) prolong survival in prostate cancer (PC) models. Few human trials tested weight loss on PC. No prior study tested a LCD to delay PC growth. We tested if weight loss via a LCD slowed PSA doubling time (PSADT) in overweight/obese men with biochemical recurrence (BCR) after PC treatment.
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METHODS: We conducted a multi-site pilot randomized controlled trial testing a 6-mo LCD intervention vs control on PSADT (NCT01763944). Men had BMI !24 kg/m2, received prior PC surgery or radiation, had PSA 0.4-20.0 ng/ml (3-20 if prior radiation) in the past 3 mos, and PSADT 3-36 mos. LCD men were asked to eat <20 g/carbs/day with no other limits. Controls were told to make no diet change. Arms were compared by rank-sum. Primary outcome was difference in PSADT. Secondary outcomes were weight loss, lipids, glucose metabolism markers and diet. Post-hoc analysis compared log-transformed PSADT adjusted for baseline factors via linear regression and percent with PSADT slowing.
RESULTS: 58 men were randomized and 46 completed the study (27 LCD, 19 control) . At baseline, arms were similar in age and diet but the LCD arm had lower PSA (1.2 vs 2.3 ng/ml) and shorter PSADT (37% vs 26% <9 mos). At 6-mo, while both arms ate similar amount of protein, total and saturated fats, LCD men had significantly lower median carb intake vs controls (37 vs. 157 g, p<0.001).There was no difference in PSADT by arm (p[0.68). LCD men significantly reduced weight, HDL, triglycerides and hbA1c with no difference in total cholesterol or glucose (table). After accounting for pre-study PSADT, baseline PSA, primary treatment and hemoconcentration which occurs with weight loss, PSADT was suggestively slower with LCD (p[0.08). PSADT slowed in 70% of LCD vs. 47% controls (p[0.14). All study-related adverse events were mild.
CONCLUSIONS: Among men with BCR, despite imperfect compliance, a LCD induced dramatic weight loss and did not affect PSADT implying a LCD has no adverse effects on PC growth and can safely be used by BCR patients. In post-hoc analyses adjusting for baseline differences and hemoconcentration, a LCD suggestively slowed PSADT. Further study of a LCD to slow PC growth is warranted. CONCLUSIONS:
In conclusion, we demonstrate a sustained and definitive increase in prostate cancer distant metastases in men aged !75 years. Although our observational study design cannot pinpoint the exact cause of this increase, which likely multi-factorial, this shift reverses declines in metastases at diagnoses that followed the advent of PSA screening. Continued, close monitoring of population-based shifts in disease presentation is needed to determine the downstream epidemiological sequelae on prostate cancer specific mortality.
